Evommune pays $30 million upfront to license Hinova’s oral molecular glue degrader for autoimmune pipeline

Evommune announced a deal with Hinova Pharmaceuticals to license an oral molecular glue degrader aimed at autoimmune diseases.

The agreement includes a $30 million upfront payment, split into $20 million cash and $10 million in pre‑funded warrants, and grants Evommune worldwide rights outside Greater China.

Hinova can receive up to $1.1 billion in milestones and royalties on sales outside China. The candidate, now called EVO570, targets the VAV1 protein and is slated for a Phase 1 study with a mid‑stage rheumatoid arthritis trial planned for 2027.

Analysts view the low‑cost, high‑probability bet as a way for Evommune to fill a pipeline gap after recent clinical setbacks at Hinova.